Entrepreneur
Lab-grown human eggs and sperm ‘about seven years away’

Scientists say lab-grown human sex cells could be less than a decade from reality, with major implications for fertility and reproduction.
The technology could, in theory, allow anyone to have biological children, regardless of sex, fertility or age.
Researchers are making rapid progress towards turning adult skin or blood cells into eggs and sperm through a process known as in-vitro gametogenesis (IVG) – a method that reprogrammes cells genetically to become gametes.
The technique typically starts by converting adult cells into stem cells, which are then guided into becoming primordial germ cells – the precursors to eggs and sperm.
These are placed inside a lab-grown organoid (a miniature version of an organ), which provides the biological signals needed to develop them further.
Prof Katsuhiko Hayashi, a developmental geneticist at the University of Osaka, told a meeting of the European Society of Human Reproduction and Embryology in Paris this week that his lab is about seven years away from creating viable human sperm.
Other frontrunners include a team at the University of Kyoto and California-based startup Conception Biosciences, whose Silicon Valley backers include OpenAI founder Sam Altman.
Conception’s chief executive told the Guardian the company is focused on producing clinical-grade human eggs and believes the technology could reverse population decline and open the door to human gene editing.
Hayashi said: “I feel a bit of pressure. It feels like being in a race.
“On the other hand, I always try to persuade myself to keep to a scientific sense of value.”
Hayashi’s lab has already produced baby mice with two biological fathers, suggesting the technique could one day be used by same-sex couples.
He said the lab receives emails from prospective fertility patients about once a week.
He said: “We get emails from [fertility] patients, maybe once a week.
“Some people say: ‘I can come to Japan.’ So I feel the demand from people.”
Matt Krisiloff, chief executive of Conception Biosciences, said: “Just the aspect alone of pushing the fertility clock … to potentially allow women to have children at a much older age would be huge.
“Outside of social policy, in the long term this technology might be the best tool we have to reverse population decline dynamics due to its potential to significantly expand that family planning window.”
Hayashi presented his team’s latest progress at the event, including the creation of primitive mouse sperm inside a lab-grown testicle organoid measuring about 1mm across, and the development of a human ovary organoid – a step towards growing human eggs in the lab.
Inside the artificial testes, Hayashi’s team managed to grow spermatocytes – the precursors of sperm cells – before the cells died.
He said an updated version of the organoid with a better oxygen supply could allow the cells to reach maturity.
Hayashi estimated that viable lab-grown human sperm could be about seven years away.
Creating sperm from female cells, he said, would be “technically challenging, but I don’t say it is impossible.”
He also suggested that his former colleague Prof Mitinori Saitou, based at Kyoto University, or Conception Biosciences could be ahead in the race.
“But they [Conception] are really, really secretive,” he added.
Others agreed with Hayashi’s timescale.
“People might not realise how quickly the science is moving,” said Prof Rod Mitchell, research lead for male fertility preservation in children with cancer at the University of Edinburgh.
“It’s now realistic that we will be looking at eggs or sperm generated from immature cells in the testicle or ovary in five or 10 years’ time.
“I think that is a realistic estimate rather than the standard answer to questions about timescale.”
Prof Allan Pacey, professor of andrology and deputy vice-president at the University of Manchester, said: “I think somebody will crack it. I’m ready for it. Whether society has realised, I don’t know.”
While several labs have successfully produced baby mice from lab-grown eggs, producing viable human eggs has been far more technically difficult.
A recent breakthrough in understanding how eggs stay dormant in the ovary for years could prove key.
Krisiloff declined to share detailed updates but said the company is “making really good progress on getting to a full protocol”.
In the best case, he said, the technology could reach the clinic within five years – though it may take longer.
Most researchers believe years of testing would be required to ensure that lab-grown cells do not carry genetic mutations that could be passed to embryos and future generations.
Some mice created using lab-grown cells have lived normal lifespans and been fertile.
Hayashi said: “We really need to prove that this kind of technology is safe.
“This is a big obligation.”
In the UK, using lab-grown eggs or sperm in fertility treatment is currently illegal.
The Human Fertilisation and Embryology Authority is already considering how safety could be ensured and what testing would be needed before clinical use could be approved.
Mitchell said:“The idea that you can take a cell that was never supposed to be a sperm or an egg and make it into a sperm or an egg is incredible.
“But it does bring the problem of safety. We need to be confident that it’s safe before we could ever use those cells to make a baby.”
News
Sun Pharma to acquire Organon in US$11bn deal
Entrepreneur
Women’s digital health market set to reach US$5.28 billion in 2026 – report
Entrepreneur
Future Fertility raises Series A financing to scale AI tools redefining fertility care worldwide

Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.
The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.
The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.
Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.
M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.
Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.
“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”
Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.
The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.
The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.
Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said: “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.
“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”
Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan – reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.
Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).
By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.
Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.
Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.
“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.
“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”
Find out more about Future Fertility at futurefertility.com
Entrepreneur2 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur1 week agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Fertility3 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause3 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health2 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
News4 weeks agoSelf-employment linked to better cardiovascular health outcomes in Hispanic women
Fertility3 weeks agoFlora Fertility closes US$5m seed round
News2 weeks agoResistance training has preventative effects in menopause, study finds
















